Drug Profile
RG 7841
Alternative Names: Anti-Ly6E; DLYE5953A; Lymphocyte antigen 6 complex, locus E; RG-7841Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Genentech
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; GPI-linked protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 12 Dec 2017 RG 7841 is still in phase I trials for Solid-tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in USA